Form 4: Processa Pharmaceuticals CEO Receives Stock Grant
Insider Transaction (Form 4)
George K Ng, Chief Executive Officer and a Director of Processa Pharmaceuticals, Inc., received 9,384 shares of common stock on July 26, 2026.
Summary
- Grant/award: acquired 9,384 Restricted Stock Units on July 26, 2026; holds 21,224 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
George K Ng — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-26 | Grant/award | Restricted Stock Units | 9,384 | — | — | 21,224 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-26 | Grant/award (9,384 shares) |
Keywords
insider transaction, Form 4, PCSA, Processa Pharmaceuticals, Inc., neutral, George K Ng
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.